Referências bibliográficas

• [1] ACHILLADELIS, B.; ANTONAKIS, N. The dynamics of technological innovation : the case of the pharmaceutical industry. 200 AHUJA, G.; KATILA, R. Technological Acquisition and the Innovation Performance of Acquiring Firms: A Longitudinal Study. Strategic Management Journal, v. 22, n. 3, p. 197–220, 200 AHUJA, G.; LAMPERT, C. M. Entrepreneurship in the large corporation: A longitudinal study of how established firms create breakthrough inventions. Strategic Management Journal, v. 22, n. 6–7, p. 521–543, 200 ALMEIDA, P.; HOHBERGER, J.; PARADA, P. Individual scientific collaborations and firm-level innovation. Industrial and Corporate Change, v. 20, n. 6, p. 1571–1599, 201 ANDERSSON, M.; XIAO, J. Acquisitions of start-ups by incumbent businesses: A market selection process of “high-quality” entrants? Research Policy, v. 45, n. 1, p. 272–290, 2016. BAUER, F. et al. Mergers and Acquisitions , Entrepreneurship and Innovation Article information : 2016. CARTER, P. H. et al. Investigating investment in biopharmaceutical R&D. Nature Reviews Drug Discovery, v. 15, n. 10, p. 673–674, 2016. CASSIMAN, B.; VEUGELERS, R. Are external technology sourcing strategies substitutes or complements: The case of embodied versus disembodied technology acquisition. v. 3, n. 672, p. 1–22, 2007. CHAKRABARTI, A., HAUSCHILDT, J., SUVERKRUP, C. Does it pay to acquire technological firms? In: R&D Management, 24, pg. 47-56, 1994 CLOODT, M.; HAGEDOORN, J.; VAN KRANENBURG, H. Mergers and acquisitions: Their effect on the innovative performance of companies in high-tech industries. Research Policy, v. 35, n. 5, p. 642–654, 2006. COHEN, W. M.; LEVINTHAL, D. A. Absorptive Capacity : A New Perspective on and Innovation Learning. Administrative Science Quarterly - Special Issue: Technology, v. 35, n. 1, p. 128–152, 1990. COLOMBO, M. G.; GRILLI, L. Founders’ human capital and the growth of new technology-based firms: A competence-based view. Research Policy, v. 34, n. 6, p. 795–816, 2005. COLOMBO, M. G.; PIVA, E. Firms’ genetic characteristics and competence-enlarging strategies: A comparison between academic and non-academic high-tech start-ups. Research Policy, v. 41, n. 1, p. 79–92, 2012. COMANOR, W. S.; SCHERER, F. M. Mergers and innovation in the pharmaceutical industry. Journal of Health Economics, v. 32, n. 1, p. 106–113, 2013. DE MATOS, M. M. CHANGES IN INNOVATION DYNAMICS OF THE PHARMACEUTICAL INDUSTRY : [s.l.] Tese, 2016. DESYLLAS, P.; HUGHES, A. Sourcing technological knowledge through corporate acquisition: Evidence from an international sample of high technology firms. Journal of High Technology Management Research, v. 18, n. 2, p. 157–172, 2007. DESYLLAS, P.; HUGHES, A. Do high technology acquirers become more innovative? Research Policy, v. 39, n. 8, p. 1105–1121, 2010. DIMASI, J. A. New Drug Innovation and Pharmaceutical Industry Structure: Trends in the Output of Pharmaceutical Firms. Drug Information Journal, v. 34, n. 4, p. 1169–1194, 2000. EJERMO, O.; XIAO, J. Entrepreneurship and survival over the business cycle: How do new technology-based firms differ? Small Business Economics, v. 43, n. 2, p. 411–426, 2014. GAMBARDELLA, A. Science and Innovation: The U.S. Pharmaceutical industry During the 1980’s, Cambridge University Press, Cambridge, 1995. GERPOTT, T. J. Successful integration of R&D functions after acquisitions: An exploratory empirical study. R&D Management, v. 25, n. 2, p. 161–178, 1995. GLEADLE, P. et al. Restructuring and innovation in pharmaceuticals and biotechs: The impact of financialisation. Critical Perspectives on Accounting, v. 25, n. 1, p. 67–77, 2014. GRABOWSKI, H. G.; VERNON, J. M. Returns to R&D on new drug introductions in the 1980s. Journal of Health Economics, v. 13, n. 4, p. 383–406, 1994. GRABOWSKI, H. G.; VERNON, J. M. The determinants of pharmaceutical research and development expenditures. Journal of Evolutionary Economics, v. 10, p. 201–215, 2000. GRIGORIOU, K.; ROTHAERMEL, F. T. Structural Microfoundations of Innovation: The Role of Relational Stars. Journal of Management, v. 40, n. 2, p. 586–615, 2014. HAGEDOORN, J.; DUYSTERS, G. The Effect of Mergers and Acquisitions on the Technological Performance of Companies in a High-tech Environment. Technology Analysis & Strategic Management, v. 14, n. 1, p. 67–85, 2002a. HAGEDOORN, J.; DUYSTERS, G. External sources of innovative capabilities: The preference for strategic alliances or mergers and acquisitions. Journal of Management Studies, v. 39, n. 2, p. 167–188, 2002b. HALL, B. H.; JAFFE, A. B.; TRAJTENBERG, M. THE NBER PATENT CITATIONS DATA FILE: LESSONS, INSIGHTS AND METHODOLOGICAL TOOLSNo Title: Working paper 8498. [s.l: s.n.]. HESS, A.; ROTHAERMEL, F. T. WHEN ARE ASSETS COMPLEMENTARY? STAR SCIENTISTS, STRATEGIC ALLIANCES, AND INNOVATION IN THE PHARMACEUTICAL INDUSTRY. Strategic Management Journal, v. 32, p. 8950909, 201 HOHBERGER, J. Does it pay to stand on the shoulders of giants? An analysis of the inventions of star inventors in the biotechnology sector. Research Policy, v. 45, n. 3, p. 682–698, 2016. HOPKINS, M. M. et al. The myth of the biotech revolution: An assessment of technological, clinical and organisational change. Research Policy, v. 36, n. 4, p. 566–589, 2007. HOPKINS, M. M. et al. Buying big into biotech: Scale, financing, and the industrial dynamics of UK biotech, 1980-2009. Industrial and Corporate Change, v. 22, n. 4, p. 903–952, 2013. HUSSINGER, K. On the importance of technological relatedness: SMEs versus large acquisition targets. Technovation, v. 30, n. 1, p. 57–64, 2010. LAURSEN, K.; SALTER, A. J. The paradox of openness: Appropriability, external search and collaboration. Research Policy, v. 43, n. 5, p. 867–878, 2014. MAKRI, M.; HITT, A.; LANE, P. Complementary Technologies, Knowledge Relatedness and Invention Outcomes in High Technology Mergers and Acquisitions. In: Strategic Management Journal, 31, pp. 602-628, 2010. MAKRI, M.; LANE, P. J. Responding to technological maturity: A socio-cognitive model of science and innovation in technological communities. Journal of High Technology Management Research, v. 18, n. 1, p. 1–14, 2007. MALERBA, F.; ORSENIGO, L. The evolution of the pharmaceutical industry. Business History, v. 57, n. 5, p. 664–687, 2015. MUNOS, B. Lessons from 60 years of pharmaceutical innovation. Nature reviews. Drug discovery, v. 8, n. 12, p. 959–968, 2009. NIGHTINGALE, P. Economies of scale in experimentation: knowledge and technology in pharmaceutical R&D. Industrial & Corporate Change, v. 9, n. 2, p. 315, 2000. NIGHTINGALE, P.; MARTIN, P. The myth of the biotech revolution. Trends in Biotechnology, v. 22, n. 11, p. 564–569, 2004. NORBÄCK, P.; PERSSON, L. Born to be global and the globalization process. 2013. NOVELLI, E. An examination of the antecedents and implications of patent scope. Research Policy, v. 44, n. 2, p. 493–507, 2015. OETTL, A. Reconceptualizing stars: Scientist helpfulness and peer performance. Management Science, v. 58, n. 6, p. 1122–1140, 2012. PAUL, S. M. et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nature reviews. Drug discovery, v. 9, n. 3, p. 203–14, 2010. PENROSE, Edith T. The theory of the growth ofthe firm. New York: Sharpe, 1959. POWELL, W. W. et al. the Life Sciences Network Dynamics and Field Evolution : The Growth of Interorganizational Collaboration in the Life Sciences American Journal of sociology, v. 110, n. 4, p. 1132–1205, 2013. POWELL W.W. KOPUT, K. W. S.-D. L. Collaboraation and the locus of innovation: networks of learning in biotechnology. Adminisstrative Science Quarterly, v. 41, n. 1, p. 116–145, 1996. QUÉRÉ, M. The post-genome era: rupture in the organization of the life science industry? In: McKELVEY, M., RICKNE, A., LAAGE-HELLMAN, J. The Economic Dynamics of Modern Biotechnology, Edward Elgar, Northhampton, USA, 2004 SCHWARTZMAN, D. Innovation in the Pharmaceutical Industry, The Johns Hopkins university Press, Baltimore, Maryland, 1976 SCHWARTZMAN, D.; COGNAT, A. Has Pharmaceutical Research Become More Scientifk ?. 1996. SCHWEIZER, L. Organizational integration of acquired biotechnology companies into pharmaceutical companies: The need for a hybrid approach. Academy of Management Journal, v. 48, n. 6, p. 1051–1074, 2005. SHARP, M. STEEP Discussion Paper No 28 The Science of Nations : European Multinationals and American Biotechnology. v. 44, n. 28, 1996. STRUMSKY, D.; LOBO, J. Identifying the sources of technological novelty in the process of invention. Research Policy, v. 44, n. 8, p. 1445–1461, 2015. SZÜCS, F. M&A and R&D: Asymmetric Effects on acquirers and targets? Research Policy, v. 43, n. 7, p. 1264–1273, 2014. TRAJTENBERG, M.; HENDERSON, R.; JAFFE, A. University Versus Corporate Patents: A Window On The Basicness Of Invention. Economics of Innovation and New Technology, v. 5, n. 1, p. 19–50, 1997. XIAO, J. Ownership Change , Multinationals , and Growth of New Technology - Based Firms Ownership Change , Multinationals , and Growth of New Technology - Based Firms. [s.l: s.n.]. XIAO, J. The effects of acquisition on the growth of new technology- based firms : Do different types of acquirers matter ? Small Business Economics, p. 487–504, 2015. ZUCKER, L. G.; DARBY, M. R. Present at the biotechnological revolution: transformation of technological identity for a large incumbent pharmaceutical firm. Research Policy, v. 26, n. 4–5, p. 429–446, 1997. ZUCKER, L. G.; DARBY, M. R. Star Scientists, Innovation and Regional and National Immigration. Entrepreneurship and Openness Entrepreneurship and Openness Theory and Evidence, 2009. ZUCKER, L. G.; DARBY, M. R.; ARMSTRONG, J. S. COMMERCIALIZING KNOWLEDGE: UNIVERSITY SCIENCE, KNOWLEDGE CAPTURE, AND FIRM PERFORMANCE IN BIOTECHNOLOGY. NBER Working Paper Series, n. Working Paper 8499, 2001